Effectiveness of a new bioequivalent formulation of oseltamivir (Enfluvir® ) on 2010–2011 seasonal influenza viruses: an open phase IV study

• Published in: International journal of infectious diseases Vol. 16; no. 4; pp. e273 - e278
• Main Authors: Ceyhan, Mehmet, Karadag Oncel, Eda, Badur, Selim, Ciblak, Meral Akcay, Alhan, Emre, Celik, Umit Sızmaz, Kurugol, Zafer, Saz, Eylem Ulas, Ozsurekci, Yasemin, Celik, Melda, Parlakay, Aslınur Ozkaya
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.04.2012
• Subjects: Adolescent; Antiviral Agents - therapeutic use; Child; Child, Preschool; Children; Female; Humans; Infant; Infectious Disease; Influenza; Influenza, Human - diagnosis; Influenza, Human - drug therapy; Male; Oseltamivir; Oseltamivir - therapeutic use; Prospective Studies; Pulmonary/Respiratory; Reverse Transcriptase Polymerase Chain Reaction; Symptom duration; Treatment Outcome; Oseltamivir; Symptom duration; Children; Influenza
• ISSN: 1201-9712; 1878-3511
• DOI: 10.1016/j.ijid.2011.12.008

Summary Objective The aim of this multicenter prospective study was to evaluate the efficacy of a new bioequivalent formulation of oseltamivir for the treatment of influenza A, influenza B, and H1N1 during the 2010–2011 influenza season. Methods We compared the symptoms and signs of 300 pediatric patients presenting to three university hospitals with an influenza-like illness between January and March 2011. Nasal swab specimens were collected from all children and tested by reverse-transcription polymerase chain reaction (RT-PCR) for influenza viruses. After randomization, half of the participants were prescribed oseltamivir, while the other half were observed conservatively. Forty patients who were followed-up for influenza prior to the study were also included in the evaluation. Results Influenza was confirmed by RT-PCR in 129 children, 71 of whom were prescribed oseltamivir. The durations of the symptoms fever, cough, nasal congestion, and rhinorrhea were significantly shorter for patients who were treated with oseltamivir compared with untreated patients ( p < 0.002 for all symptoms). Early initiation of oseltamivir therapy (within 48 h of the onset of symptoms) was associated with more favorable outcomes and an earlier recovery than in patients for whom treatment was delayed (beyond 48 h). Thirty-seven patients (28.7%) had H1N1, 44 (34.1%) had influenza A, 46 (35.7%) had influenza B, one (0.8%) had H1N1 plus influenza A, and one (0.8%) had influenza A plus influenza B viruses. In the comparison of the duration of symptoms according to the different virus types, a statistically significant difference was only observed in patients with influenza B who had a longer duration of cough ( p < 0.001), nasal congestion ( p < 0.001), and rhinorrhea ( p < 0.001). Conclusions Oseltamivir is an effective treatment for the management of seasonal influenza and H1N1, and should be initiated immediately without waiting for laboratory confirmation of diagnosis.